98627-22-6

Basic information

• Product Name: Benzyl-PEG3-Tos
• Synonyms: Benzyl-PEG3-Tos;2-(2-(benzyloxy)ethoxy)ethyl 4-methylbenzenesulfonate;2-(2-(benzyloxy)ethoxy)ethyl 4-methylbenzenesulfonate(WXC06918)
• CAS NO: 98627-22-6
• Molecular Formula: C₁₈H₂₂O₅S
• Molecular Weight: 350.42928
• Mol File: 98627-22-6.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzyl-PEG3-Tos(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl-PEG3-Tos(98627-22-6)
• EPA Substance Registry System: Benzyl-PEG3-Tos(98627-22-6)

Safety Data

• Hazardous Substances Data: 98627-22-6(Hazardous Substances Data)

Usage

Description

Benzyl-PEG3-Tos is a PEG linker with an acid labile, benzyl protecting group. The tosyl group is a good leaving group. The hydrophilic PEG linker increases the water solubility of the compound in aqueous media.

Upstream product

• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 2050-25-1 diethylene glycol monobenzyl ether 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 105891-53-0 1-((2-(2-(2-(2-(2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)methyl)benzene 
• 1243655-69-7 1,2-dibromo-4,5-bis[2'-(2-benzyloxyethoxy)ethoxy]benzene 
• 152523-64-3 2,2'-bis<2-<2-(phenylmethoxy)ethoxy>ethoxy>-1,1'-binaphthalene 
• 1260001-87-3 ((2-(2-azidoethoxy)ethoxy)methyl)benzene 
• 88454-83-5 ((2-(2-iodoethoxy)ethoxy)methyl)benzene 
• 151801-12-6 3-(7-benzyloxy-2,5-dioxaheptyl)-3-methyl-1,5,8,11-tetraoxacyclotridecane 
• 143173-32-4 C₂₄H₃₂O₅ 
• 117666-59-8 (7S,7'S)-7,7'-bis(1,17-dibenzyloxy-3,6,9,12,15-pentaoxaheptadecane) 
• 98627-23-7 13-[2-(2-Benzyloxy-ethoxy)-ethyl]-5-benzyloxymethyl-1,4,7,10-tetraoxa-13-aza-cyclopentadecane 
• 155580-07-7 2,2'-Bis<2-<2-(phenylmethoxy)ethoxy>ethoxy>-<1,1'-binaphthalene>-3-carboxylic acid methyl ester 

Relevant articles and documents

SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN?PROTEIN INTERACTION

Disclosed are inhibitors for the β-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for β-catenin/B-cell lymphoma 9 over β-catenin/ E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.

HETEROCYCLIC COMPOUND

One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.

BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.